Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to evaluate the efficacy and safety of WX-0593 vs.
crizotinib in patients with ALK-positive non-small cell lung cancer who had not received
prior systemic therapy